



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PR208a : Prostate cancer tissue array, with pathology grade, Gleason grade, Gleason score, TNM and clinical stage, 64 cases/192 cores, replacing PR208

| | | |
|--------------------|---|--|
| Microarray Panel | Prostate adenocarcinoma tissue microarray, containing 58 cases of adenocarcinoma, 6 normal prostate tissue, triplicate cores per case | |
| Cores | 192 | |
| Cases | 64 | |
| Row number | 12 | |
| Column number | 16 | |
| Core Diameter (mm) | 1 | |
| Thickness (µm) | 5 | |
| Tissue Array Type | FFPE | |
| Species | Human | |
| Applications | Routine histology procedures including Immunohistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found at our support page. | |
| Notes | <p>1. TMA slides were sectioned and stored at 4°C and may not be fresh cut, but still suitable for IHC. Please request fresh cut if experiment involves phospho-specific antibodies, RNA studies, FISH or ISH, etc. A minimum of 3 slides per TMA must be purchased to cover the cost of trimming for fresh sectioning. 2. Most TMA slides were not coated with an extra layer of paraffin (tissue cores can be easily seen on the glass). To prevent tissue detachment during antigen retrieval, unbaked slides must be baked for at least 30 to 120 minutes at 60°C. before putting into xylene for de-paraffinization. Baked slides were sent out baked for 2 hours.</p> <p>In the following specsheet, "*" means invalid core; "-" means no applicable or negative in IHC markers.</p> | |

Mouseover and click individual cores to view high resolution images.



Legend: Pro - Prostate
● - Malignant tumor, ● - Malignant tumor (stage I), ● - Malignant tumor (stage IIA), ● - Malignant tumor (stage IIB), ● - Malignant tumor (stage III), ● - Malignant tumor (stage IV), ● - Normal tissue

, tissue IDs are available in exported Excel files.

| Pos. | No. | Age | Sex | Organ/Anatomic Site | Pathology diagnosis | TNM | Grade | Stage | Type | Gleason Score | Gleason Grade | Image |
|------|-----|-----|-----|---------------------|---------------------|--------|-------|-------|-----------|---------------|---------------|-------|
| A1 | 1 | 68 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+3 | 3 | |
| A2 | 2 | 68 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+3 | 3 | |
| A3 | 3 | 68 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+3 | 3 | |
| A4 | 4 | 63 | M | Prostate | Adenocarcinoma | T3N0M0 | 1 | III | Malignant | 1+2 | 2 | |
| A5 | 5 | 63 | M | Prostate | Adenocarcinoma | T3N0M0 | 1 | III | Malignant | 1+2 | 2 | |
| A6 | 6 | 63 | M | Prostate | Adenocarcinoma | T3N0M0 | 1 | III | Malignant | 1+2 | 2 | |
| A7 | 7 | 74 | M | Prostate | Adenocarcinoma | T4N1M0 | 1 | IV | Malignant | 1+2 | 2 | |
| A8 | 8 | 74 | M | Prostate | Adenocarcinoma | T4N1M0 | 1 | IV | Malignant | 1+2 | 2 | |
| A9 | 9 | 74 | M | Prostate | Adenocarcinoma | T4N1M0 | 1 | IV | Malignant | 1+2 | 2 | |
| A10 | 10 | 26 | M | Prostate | Adenocarcinoma | T2N0M0 | - | I | Malignant | - | - | |
| A11 | 11 | 26 | M | Prostate | Adenocarcinoma | T2N0M0 | - | I | Malignant | - | - | |
| A12 | 12 | 26 | M | Prostate | Adenocarcinoma | T2N0M0 | - | I | Malignant | - | - | |
| A13 | 13 | 66 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+2 | 2 | |
| A14 | 14 | 66 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+2 | 2 | |
| A15 | 15 | 66 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+2 | 2 | |
| A16 | 16 | 66 | M | Prostate | Adenocarcinoma | T3N1M1 | 1 | IV | Malignant | 1+2 | 2 | |
| B1 | 17 | 66 | M | Prostate | Adenocarcinoma | T3N1M1 | 1 | IV | Malignant | 1+2 | 2 | |
| B2 | 18 | 66 | M | Prostate | Adenocarcinoma | T3N1M1 | 1 | IV | Malignant | 1+2 | 2 | |
| B3 | 19 | 57 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+3 | 3 | |
| B4 | 20 | 57 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+3 | 3 | |
| B5 | 21 | 57 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+3 | 3 | |
| B6 | 22 | 71 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+2 | 2 | |

| | | | | | | | | | | | |
|-----|----|----|---|----------|-------------------------|--------|---|-----|-----------|-----|---|
| B7 | 23 | 71 | M | Prostate | Adenocarcinoma | T2N0M0 | - | I | Malignant | - | - |
| B8 | 24 | 71 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+2 | 2 |
| B9 | 25 | 75 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+2 | 2 |
| B10 | 26 | 75 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+2 | 2 |
| B11 | 27 | 75 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+2 | 2 |
| B12 | 28 | 72 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| B13 | 29 | 72 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| B14 | 30 | 72 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| B15 | 31 | 73 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| B16 | 32 | 73 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| C1 | 33 | 73 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| C2 | 34 | 67 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| C3 | 35 | 67 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| C4 | 36 | 67 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| C5 | 37 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+3 | 3 |
| C6 | 38 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+3 | 3 |
| C7 | 39 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 1 | I | Malignant | 2+3 | 3 |
| C8 | 40 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| C9 | 41 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| C10 | 42 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| C11 | 43 | 83 | M | Prostate | Adenocarcinoma | T4N1M1 | - | IV | Malignant | - | - |
| C12 | 44 | 83 | M | Prostate | Adenocarcinoma | T4N1M1 | - | IV | Malignant | - | - |
| C13 | 45 | 83 | M | Prostate | Adenocarcinoma | T4N1M1 | - | IV | Malignant | - | - |
| C14 | 46 | 70 | M | Prostate | Adenocarcinoma | T2N1M1 | 2 | IV | Malignant | 3+4 | 4 |
| C15 | 47 | 70 | M | Prostate | Adenocarcinoma | T2N1M1 | 2 | IV | Malignant | 3+4 | 4 |
| C16 | 48 | 70 | M | Prostate | Adenocarcinoma | T2N1M1 | 2 | IV | Malignant | 3+4 | 4 |
| D1 | 49 | 56 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| D2 | 50 | 56 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| D3 | 51 | 56 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| D4 | 52 | 75 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 2+4 | 4 |
| D5 | 53 | 75 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 2+4 | 4 |
| D6 | 54 | 75 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 2+4 | 4 |
| D7 | 55 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| D8 | 56 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| D9 | 57 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| D10 | 58 | 71 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| D11 | 59 | 71 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| D12 | 60 | 71 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| D13 | 61 | 82 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| D14 | 62 | 82 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| D15 | 63 | 82 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| D16 | 64 | 73 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+3 | 3 |
| E1 | 65 | 73 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+3 | 3 |
| E2 | 66 | 73 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+3 | 3 |
| E3 | 67 | 60 | M | Prostate | Adenocarcinoma | T3N1M0 | 2 | IV | Malignant | 3+4 | 4 |
| E4 | 68 | 60 | M | Prostate | Adenocarcinoma | T3N1M0 | 2 | IV | Malignant | 3+4 | 4 |
| E5 | 69 | 60 | M | Prostate | Adenocarcinoma | T3N1M0 | 2 | IV | Malignant | 3+4 | 4 |
| E6 | 70 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| E7 | 71 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| E8 | 72 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| E9 | 73 | 69 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| E10 | 74 | 69 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| E11 | 75 | 69 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| E12 | 76 | 62 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| E13 | 77 | 62 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| E14 | 78 | 62 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| E15 | 79 | 73 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| E16 | 80 | 73 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| F1 | 81 | 73 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| F2 | 82 | 61 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| F3 | 83 | 61 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| F4 | 84 | 61 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| F5 | 85 | 70 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+4 | 4 |
| F6 | 86 | 70 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+4 | 4 |
| F7 | 87 | 70 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+4 | 4 |
| F8 | 88 | 73 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| F9 | 89 | 73 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| F10 | 90 | 73 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| F11 | 91 | 76 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| F12 | 92 | 76 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| F13 | 93 | 76 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | I | Malignant | 3+3 | 3 |
| F14 | 94 | 69 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+3 | 3 |
| F15 | 95 | 69 | M | Prostate | Adenocarcinoma (sparse) | T3N0M0 | - | III | Malignant | - | - |

| | | | | | | | | | | | |
|-----|-----|----|---|----------|----------------|--------|---|-----|-----------|-----|---|
| F16 | 96 | 69 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+3 | 3 |
| G1 | 97 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 3+5 | 5 |
| G2 | 98 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 3+5 | 5 |
| G3 | 99 | 65 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 3+5 | 5 |
| G4 | 100 | - | M | Prostate | Adenocarcinoma | T2N0M0 | - | IIB | Malignant | - | - |
| G5 | 101 | - | M | Prostate | Adenocarcinoma | T2N0M0 | - | IIB | Malignant | - | - |
| G6 | 102 | - | M | Prostate | Adenocarcinoma | T2N0M0 | - | IIB | Malignant | - | - |
| G7 | 103 | 62 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+4 | 4 |
| G8 | 104 | 62 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+4 | 4 |
| G9 | 105 | 62 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+4 | 4 |
| G10 | 106 | 76 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 4+5 | 5 |
| G11 | 107 | 76 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 4+5 | 5 |
| G12 | 108 | 76 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 4+5 | 5 |
| G13 | 109 | 82 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+4 | 4 |
| G14 | 110 | 82 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+4 | 4 |
| G15 | 111 | 82 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+4 | 4 |
| G16 | 112 | 64 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 4+5 | 5 |
| H1 | 113 | 64 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 4+5 | 5 |
| H2 | 114 | 64 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 4+5 | 5 |
| H3 | 115 | 64 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+3 | 3 |
| H4 | 116 | 64 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+3 | 3 |
| H5 | 117 | 64 | M | Prostate | Adenocarcinoma | T3N0M0 | 2 | III | Malignant | 3+3 | 3 |
| H6 | 118 | 78 | M | Prostate | Adenocarcinoma | T4N0M0 | 3 | IV | Malignant | 4+5 | 5 |
| H7 | 119 | 78 | M | Prostate | Adenocarcinoma | T4N0M0 | 3 | IV | Malignant | 4+5 | 5 |
| H8 | 120 | 78 | M | Prostate | Adenocarcinoma | T4N0M0 | 3 | IV | Malignant | 4+5 | 5 |
| H9 | 121 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 3+5 | 5 |
| H10 | 122 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 3+5 | 5 |
| H11 | 123 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 3+5 | 5 |
| H12 | 124 | 66 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 3+5 | 5 |
| H13 | 125 | 66 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 3+5 | 5 |
| H14 | 126 | 66 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 3+5 | 5 |
| H15 | 127 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| H16 | 128 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| I1 | 129 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| I2 | 130 | 73 | M | Prostate | Adenocarcinoma | T4N0M0 | - | IV | Malignant | - | - |
| I3 | 131 | 73 | M | Prostate | Adenocarcinoma | T4N0M0 | 3 | IV | Malignant | 5+5 | 5 |
| I4 | 132 | 73 | M | Prostate | Adenocarcinoma | T4N0M0 | 3 | IV | Malignant | 5+5 | 5 |
| I5 | 133 | 63 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 4+5 | 5 |
| I6 | 134 | 63 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 4+5 | 5 |
| I7 | 135 | 63 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 4+5 | 5 |
| I8 | 136 | 60 | M | Prostate | Adenocarcinoma | T3N1M0 | 3 | IV | Malignant | 5+5 | 5 |
| I9 | 137 | 60 | M | Prostate | Adenocarcinoma | T3N1M0 | 3 | IV | Malignant | 5+5 | 5 |
| I10 | 138 | 60 | M | Prostate | Adenocarcinoma | T3N1M0 | 3 | IV | Malignant | 5+5 | 5 |
| I11 | 139 | 80 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 4+5 | 5 |
| I12 | 140 | 80 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 4+5 | 5 |
| I13 | 141 | 80 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 4+5 | 5 |
| I14 | 142 | 73 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+4 | 5 |
| I15 | 143 | 73 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+4 | 5 |
| I16 | 144 | 73 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+4 | 5 |
| J1 | 145 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 3 |
| J2 | 146 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | - | IIA | Malignant | - | - |
| J3 | 147 | 64 | M | Prostate | Adenocarcinoma | T2N0M0 | 2 | IIA | Malignant | 3+4 | 4 |
| J4 | 148 | 68 | M | Prostate | Adenocarcinoma | T2N0M0 | - | IIA | Malignant | - | - |
| J5 | 149 | 68 | M | Prostate | Adenocarcinoma | T2N0M0 | - | IIA | Malignant | - | - |
| J6 | 150 | 68 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+5 | 5 |
| J7 | 151 | 87 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+4 | 5 |
| J8 | 152 | 87 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+4 | 5 |
| J9 | 153 | 87 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+4 | 5 |
| J10 | 154 | 72 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 5+4 | 5 |
| J11 | 155 | 72 | M | Prostate | Adenocarcinoma | T3N0M0 | - | III | Malignant | - | - |
| J12 | 156 | 72 | M | Prostate | Adenocarcinoma | T3N0M0 | - | III | Malignant | - | - |
| J13 | 157 | 82 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+4 | 5 |
| J14 | 158 | 82 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+4 | 5 |
| J15 | 159 | 82 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+4 | 5 |
| J16 | 160 | 62 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 4+5 | 5 |
| K1 | 161 | 62 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 4+5 | 5 |
| K2 | 162 | 62 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 4+5 | 5 |
| K3 | 163 | 77 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+5 | 5 |
| K4 | 164 | 77 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+5 | 5 |
| K5 | 165 | 77 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+5 | 5 |
| K6 | 166 | 60 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+5 | 5 |
| K7 | 167 | 60 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+5 | 5 |
| K8 | 168 | 60 | M | Prostate | Adenocarcinoma | T2N0M0 | 3 | IIB | Malignant | 5+5 | 5 |

| | | | | | | | | | | | |
|-----|-----|----|---|---------------|----------------------------------|--------|---|-----|-----------|-----|---|
| K9 | 169 | 81 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 5+4 | 5 |
| K10 | 170 | 81 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 5+4 | 5 |
| K11 | 171 | 81 | M | Prostate | Adenocarcinoma | T3N0M0 | 3 | III | Malignant | 5+4 | 5 |
| K12 | 172 | 70 | M | Prostate | Small acinar cancer | T2N0M0 | - | IIA | Malignant | - | - |
| K13 | 173 | 70 | M | Prostate | Small acinar cancer | T2N0M0 | - | IIA | Malignant | - | - |
| K14 | 174 | 70 | M | Prostate | Small acinar cancer | T2N0M0 | - | IIA | Malignant | - | - |
| K15 | 175 | 45 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| K16 | 176 | 45 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L1 | 177 | 45 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L2 | 178 | 40 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L3 | 179 | 40 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L4 | 180 | 40 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L5 | 181 | 30 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L6 | 182 | 30 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L7 | 183 | 30 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L8 | 184 | 32 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L9 | 185 | 32 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L10 | 186 | 32 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L11 | 187 | 30 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L12 | 188 | 30 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L13 | 189 | 30 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L14 | 190 | 35 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L15 | 191 | 35 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| L16 | 192 | 35 | M | Prostate | Prostate tissue | - | - | - | Normal | - | - |
| - | 0 | 42 | M | Adrenal gland | Pheochromocytoma (tissue marker) | - | - | - | Malignant | - | - |

TNM grading:

T - Primary tumor

Tx - Primary tumor cannot be assessed

T0 - No evidence of primary tumor

Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria

T1 - Tumor invades submucosa

T2 - Tumor invades muscularis propria

T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.

T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes

Nx - Regional lymph nodes cannot be assessed

N0 - No regional lymph node metastasis

N1 - Metastasis in 1 to 3 regional lymph nodes

N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis

Mx - Distant metastasis cannot be assessed

M0 - No distant metastasis

M1 - Distant metastasis

AMSBIO | www.amsbio.com | info@amsbio.com

 **UK & Rest of the World**
184 Park Drive, Milton Park
Abingdon OX14 4SE, UK
T: +44 (0)1235 828 200
F: +44 (0) 1235 820 482

 **North America**
1035 Cambridge Street,
Cambridge, MA 02141
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218

 **Germany**
Bockenheimer Landstr. 17/19
60325 Frankfurt/Main
T: +49 (0) 69 779099
F: +49 (0) 69 13376880

 **Switzerland**
Centro Nord-Sud 2E
CH-6934 Bioggio-Lugano
T: +41(0) 91 604 55 22
F: +41(0) 91 605 17 85